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Abstract
Background: Human papillomaviruses (HPV) are causally associated with ano-genital and a subset of head and
neck cancers. Rising incidence of HPV+ anal cancers and head and neck cancers have now been demonstrated in
the developed world over the last decade. The majority of published data on HPV prevalence at the anal and oro-
pharyngeal sites are from studies of higher-risk populations. There is a paucity of data on the prevalence of HPV at
non-cervical sites in lower risk, non-HIV+ women and this study was designed to provide initial pilot data on a
population of women recalled for colposcopy as part of the UK cervical screening programme.
Methods: 100 non-HIV+ women with abnormal cervical cytology, attending clinic for colposcopic examination
were recruited. Swabs from the oro-pharyngeal, anal and cervical sites were taken and DNA extracted. HPV
detection and genotyping were performed using a standardised, commercially available PCR-line blot assay, which
is used to genotype 37 HPV subtypes known to infect the ano-genital and oro-pharyngeal areas. Strict sampling
and laboratory precautions were taken to prevent cross-contamination.
Results: There was a very high prevalence of HPV infection at all three sites: 96.0%, 91.4% and 92.4% at the cervix,
anus and oro-pharynx, respectively. Multiple HPV subtype infections were dominant at all 3 mucosal sites. At least
one or more HR genotype was present at both the cervix/anus in 39/52 (75.0%) patients; both the cervix/oro-pharynx
in 48/56 (85.7%) patients; and both the anus/oro-pharynx in 39/52 (75.0%) patients. HPV 16 infection was highly
dominant across all mucosal sites, with over a 2-fold increase over the next most prevalent subtype (HPV 31).
Conclusions: Women with abnormal smears have widespread infection with high-risk HPV at the cervical, anal and
oro-pharyngeal mucosal sites and may represent a higher risk population for HPV disease in the future.
Background
Human papillomavirus (HPV) is associated with 99.7% of
cervical cancer cases [1] and implicated in the pathogen-
esis of other ano-genital malignancies such as anal, vulvar,
penile and head and neck cancers. Of these, anal cancer is
the most strongly associated with HPV (~90%), yet much
less is known of the natural history of anal compared to
cervical infection. Anal cancer is a relatively uncommon
malignancy (incidence ~1 per 100,000), but rates have
been increasing steadily among both men and women in
Western Europe and the USA over the last three decades,
with a ratio of women to men of 3:2 in the UK.
Head and neck cancer is the 6
th most common cancer
grouping worldwide [2]. There is accumulating evidence
for HPV involvement in a subset of these cancers (~40-
60%), indicating a striking increase in the HPV+ subset
over the last few decades [3,4], while the fraction attribu-
table to the traditional risk factors of heavy tobacco
smoking and alcohol consumption has fallen gradually
[5].
HPV prevalence data from either the anal or oral site in
men who have sex with men (MSM) and high-risk women
such as sex workers or HIV+ women have been published.
However, little is known of the prevalence in women from
the general population from these non-cervical sites, and
to our knowledge, no reports of concurrent infection rates
at three different mucosal sites in women have been
published.
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from cervical and non-cervical sites, specifically the anal
canal and oro-pharyngeal mucosa, in women attending
ac o l p o s c o p yc l i n i cw i t ha bnormal cervical cytology
results.
Methods
This cross-sectional pilot HPV prevalence analysis was
approved by the local research ethics committee (09/
H0304/27) and designed to provide initial data on concur-
rent HPV infection over several mucosal sites. Over a per-
iod of eight months, 100 women were recruited as they
attended colposcopy clinic at Addenbrooke’sH o s p i t a l ,
Cambridge, after at least one abnormal smear result in the
national cervical screening programme. Written informed
consent was obtained from all participants. HIV status was
self-declared at recruitment, and HIV+ women excluded
from the study. These women were then anonymised
prior to entry to the study, and results from the study not
disclosed to the women (anonymisation unbroken).
Trained medical personnel collected exfoliated cells
from the mucosae of the anal canal and oro-pharynx using
Dacron swabs. Cervical cell samples were collected using a
Cervex brush. Strict protocols were followed to prevent
cross-contamination of samples between sites (intra-
patient) and between patients during collection and pro-
cessing, involving immediate transfer of acquired cells into
labelled, sterile containers of normal saline which were
then sealed until processing under clean laboratory condi-
tions at biosafety level 2. DNA was extracted within two
hours of collection using the DNeasy Blood and Tissue Kit
(QIAGEN Ltd, UK) according to a modified protocol in a
designated “clean” area. In brief, saline solutions contain-
ing debris from swabs were centrifuged at 3000 rpm at
4°C for 15 minutes and the cell pellets resuspended in
400 μl phosphate buffered saline (PBS), before DNA
extraction according to the manufacturer’si n s t r u c t i o n s .
T h eR o c h eL i n e a rA r r a yH P Vg e n o t y p i n gt e s t( R o c h e
Diagnostics, Burgess Hill, UK) was utilised to detect and
genotype 37 anogenital HPVs, according to the manufac-
turer’si n s t r u c t i o n s .
Histology results were provided by the clinical pathol-
ogy service at Addenbrooke’s Hospital in line with cur-
rent practice. Biopsy or large loop excision of the
transformation zone (LLETZ) was performed on women
who had detectable aceto-white lesions at colposcopy.
Patients who had no areas of aceto-white staining were
deemed to have normal colposcopy. Results were made
available to researchers two weeks post-consultation.
Patients were graded into low grade (LG) and high grade
(HG) on the basis of their initial referral cytology results.
Lesions visible at colposcopy were biopsied and, if neces-
sary, reclassified on the basis of the histology using the
most severe grading from either cytology or histology.
Results
A total of 100 women were recruited into the study with
a mean age of 34.1 years. 93% of the study population
were of Caucasian origin, either white British or white
other; the remaining patients declined a response. For
available basic demographic data, see Table 1. In the final
analysis, there were 44 LG patients and 56 HG patients
classed as such on the basis of their smear or histology
results, having mean ages of 35.4 and 32.9 years,
respectively.
In LG patients, HPV was detected in 43/44 (97.8%) cer-
vical, 41/41 (100%) anal and 42/44 (95.4%) oro-pharyn-
geal samples (Table 2). In HG patients, HPV was
detected in 53/56 (94.6%) cervical, 43/52 (82.7%) anal
and was 50/56 (89.3%) oro-pharyngeal samples (Table 2).
Overall, the prevalence of HPV infection at these sites
was 96.0%, 91.4% and 92.4% for the cervix, anus and oro-
pharynx, respectively.
In HPV-positive patients, multiple infection was highly
prevalent at all three mucosal sites (Table 2 and 2). In LG
patients, infections were found to be multiple in 32/43
(74.4%) cervical, 33/41 (80.5%) anal and 29/42 (69.0%)
oro-pharyngeal samples. In HG patients, infections were
found to be multiple in 45/53 (84.9%) cervical, 34/43
(79.0%) anal and 34/50 (68.0%) oro-pharyngeal samples.
Multiple infection at the cervix did not convey increased
risk of association with either LG or HG cytological status
(p = 0.2116, two-tailed Fisher’s exact test).
Our data showed the concordant presence of HPV
infection in LG patients (any genotype with any genotype):
cervix/anus in 40/41 (97.5%) patients; cervix/oro-pharynx
in 41/44 (93.2%) patients; and anal/oro-pharynx in 39/41
(95.1%) patients. At least one or more HR genotype was
present at both the cervix/anus in 39/41 (95.1%) patients;
both the cervix/oro-pharynx in 41/44 (93.2%) patients; and
both the anus/oro-pharynx in 38/41 (92.7%) patients.
In HG patients, the data showed the concordant pre-
sence of HPV infection of any genotype: cervix/anus in
41/52 (78.8%) patients; cervix/oro-pharynx in 47/56
(83.9%) patients; and anal/oro-pharynx in 40/52 (76.9%)
patients. At least one or more HR genotype was present at
both the cervix/anus in 39/52 (75.0%) patients; both the
Table 1 Basic patient demographic data
Mean age of women (in years) 34.1
Current contraception (undefined) 72%
Ethnicity White British/white other 93%
Undeclared 7%
Currently smoking 26%
History of term pregnancies 59%
Education (higher degree/diploma) 45%
All patients self-reported as HIV negative.
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anus/oro-pharynx in 39/52 (75.0%) patients.
The most prevalent HPV genotype infection across all
sites in both LG and HG patients was HPV 16 (Table 3).
This was followed by HPV 31, 33, 53, 59 and 45 in des-
cending order. HPV 16 was over 2-fold higher in fre-
quency compared to the next most common genotype,
which was HPV 31, [paired t-test, two-tailed p = 0.0005],
(95% CI 10.7 - 19.59]. The next 4 genotypes were 33, 53,
59 and 45 with all other genotypes much less frequent.
HPV 56 and 66 were found to be significantly more com-
mon across the three sites in LG patients compared to
HG patients. Furthermore, HPV 56 was significantly
higher in the anal and oro-pharyngeal sites alone in LG
patients, compared to HG patients.
Discussion
To our knowledge, this is the first time concurrent data on
the presence of HPV in three different mucosal sites i.e.
the cervical, anal and oro-pharyngeal sites, has been
reported for non-immunosuppressed women. Much less is
known about the natural history of HPV infection in the
anus and oro-pharynx, compared to the cervix. Valid com-
parative data in studies of oral and anogenital HPV infec-
tion have been limited, most studies exhibiting differences
in sampling techniques and HPV detection methods,
whilst involving different risk groups and risk behaviours.
In this study, the aim was to investigate HPV prevalence
and genotypes in a population of 100 women selected by
the UK national cervical screening programme for colpo-
scopic examination. As expected, this cohort with abnor-
mal cytology demonstrated a high rate of HPV carriage in
the cervix, with an overall prevalence of 96%. Furthermore,
patients were tested for the prevalence of HPV infection at
two other main mucosal sites, which are clinically relevant
to the increasing rates of anal and head and neck cancers
observed today. Remarkably, the rates of HPV present at
these two other sites were also equally high, with an
overall prevalence of 91.4% at the anus and 92.4% at the
oro-pharynx. These findings have significant implications
for the continuing rise in observed cancers of the anus
and the oro-pharynx and strongly suggest that the oro-
pharyngeal and anal sites may be reservoirs of HPV infec-
tion with the potential to affect the dynamics of HPV
transmission within the community. It follows that post-
treatment for cervical disease, a woman should not be
declared “HPV negative” unless and until these other
major sites have been tested.
The high oral HPV prevalence in our population con-
trasts to another study, in which 25.5% of women with con-
current cervical HPV infection had detectable oral HPV [6].
In two other studies (one a prospective study in men [7],
the other a systematic review of literature [8]), oral HPV
prevalence of 1.3 - 4.5% has been reported. The observed
differences may be due to factors such as different patient
populations (men vs. women, different countries of origin),
selection bias: our patients were women who were selected
because of abnormal cervical smears, and sample sizes:
small studies are more prone to bias. Despite this, it is clear
that the majority of HPV cancers of the head and neck and
anal regions are caused by a small number of HR-types and
therefore, the use of the standardised, highly sensitive and
specific Roche Linear Array HPV DNA detection method
was valid for this study. These findings suggest that women
with HPV infection causing dysplasia at the cervix require
some further surveillance to detect and prevent develop-
ment of cancers at these other mucosal sites. Indeed, it has
been shown that there is a high risk of anal cancer develop-
ment in women with a previous history of cervical, vulval
or vaginal neoplasia or cancer [9]. Further, in a prospective
study, high incidences of vulval, vaginal and anal cancers
were found in women who had a history of CIN3 compared
to women who did not [10].
There are very limited data on HPV presence in the anal
site in non-immunosuppressed women. It has been
reported that 67% of a cohort of young women with anal
cytological abnormalities demonstrated detectable HPV
[11]. A prevalence of 42% HPV positivity in the anal site in
a cohort of “high-risk” HIV-women has also been reported
[12]. Studies also show a baseline prevalence of 27% in
healthy HIV-women from the Hawaii HPV cohort [13]. A
follow-up study from the same group reported that 70% of
women followed-up for a mean period of 1.3 years were
positive for anal HPV infection at one or more visits [14].
Another study has found that women with confirmed
gynaecological neoplasia also have a high rate of biopsy
proven anal intraepithelial abnormalities (38%) upon high-
resolution anoscopic examination [15]. Our study supports
these data and furthermore, suggests that HPV DNA test-
ing per se at the anal site is unlikely to be useful, as there
is a high rate of positivity.
Table 2 Number of prevalent HPV infections at different
sites
(a) LG patients (n = 44) No. of HPV types
Total 0 (%) 1 (%) ≥ 2 (%)
Cervical 44 1 (2.3) 11 (25) 32 (72.7)
Anal
# 41 0 (0) 8 (19.5) 33 (80.5)
Oro-pharyngeal 44 2 (4.5) 13 (29.5) 29 (65.9)
(b) HG patients (n = 56) No. of HPV types
Total 0 (%) 1 (%) ≥ 2 (%)
Cervical 56 3 (5.4) 8 (14.3) 45 (80.4)
Anal
# 52 9 (17.3) 9 (17.3) 34 (65.4)
Oro-pharyngeal 56 6 (10.7) 16 (28.6) 34 (60.7)
#missing/beta-globin negative samples were excluded from the analysis;
these differences in sampling availability were not significant
(Fisher’s exact test, 2-tailed p = 0.2414 (a) and p = 0.1183 (b)).
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Page 3 of 6Table 3 HPV prevalence at three mucosal sites (cervical, anal and oro-pharyngeal) stratified by genotype and known risk
LG patient samples (n = 129) HG patient samples (n = 164)
Cervical (n = 44) Anal (n = 41) Oro-pharyngeal (n = 44) Cervical (n = 56) Anal (n = 52) Oro-pharyngeal (n = 56)
16 (p = 0.41) 20 (45.5%) 24 (58.5%) 22 (50.0%) 33 (58.9%) 28 (53.8%) 31 (55.4%)
31 (p = 0.49) 10 (22.7%) 10 (24.4%) 13 (29.5%) 14 (25.0%) 10 (19.2%) 12 (21.4%)
High-risk (HR) & probable HR (PHR) 33 (p = 0.55) 8 (18.2%) 9 (22.0%) 10 (22.7%) 9 (16.1%) 6 (11.5%) 14 (25.0%)
53 (p = 0.083) 6 (13.6%) 10 (24.4%) 5 (11.4%) 5 (8.9%) 12 (23.1%) 3 (5.4%)
59 (p = 0.26) 6 (13.6%) 9 (22.0%) 9 (20.5%) 3 (5.4%) 7 (13.5%) 6 (10.7%)
45 (p = 0.40) 7 (15.9%) 11 (26.8%) 7 (15.9%) 6 (10.7%) 4 (7.7%) 4 (7.1%)
56 (p = 0.0004) 5 (11.4%) 7* (17.1%) 7
# (15.9%) 2 (3.6%) 1 (1.9%) 2 (3.6%)
18 (p = 0.068) 1 (2.3%) 2 (4.9%) 2 (4.5%) 6 (10.7%) 5 (9.6%) 5 (8.9%)
66 (p = 0.0059) 3 (6.8%) 5 (12.2%) 4 (9.1%) 1 (1.8%) 1 (1.9%) 1 (1.8%)
Others
a 22 23 17 31 19 23
Low-risk (LR)
b 18 16 10 12 15 8
Undetermined-risk (UDR)
c 10 10 8 7 9 3
Total 116 136 114 129 117 112
*
#prevalence of HPV56 was significantly higher in anal (p = 0.0198) and oro-pharyngeal (p = 0.0406) samples from LG patients (Fisher’s exact test, two-tailed). Only the 9 most frequent HR-HPV and PHR-HPV
subtypes have been included in the table for clarity.
acumulative occurrences of the remaining 12 HR-HPV & probable HR-HPV subtypes (26, 35, 39, 51, 52, 58, 68, 69, 70, 73, 82 and IS39).
bcumulative occurrences of
9 LR-HPV subtypes (6, 11, 40, 42, 54, 61, 72, 81 and CP6108).






















































































6The risks of sequential incident infection from cervix to
anus and vice versa, is reported to be significantly more
likely than infection with a discordant HPV type or no
previous HPV infection [16]. The route of transmission
from one anogenital site to an adjacent one is not clear
and may be by sexual or non-sexual spread.
HPV 16 was significantly the most prevalent genotype
across all three mucosal sites. Only poor to moderate
concordance rates were demonstrated between the sites
(data not shown), which may suggest that initial infection
at each of the sites could have been a separate event.
Even if infections at these sites were acquired at the same
instance, differences in the amount of viral inocula, other
factors such as infection persistence, systemic immunity
levels and effects of the local environment could all result
in high discordance in a cross-sectional study such as
this. Interestingly, the strong dominance of HPV 16 at all
sites is supportive of published data in which HPV 16 is
the predominant type found in squamous cell carcinomas
at all three mucosal sites [17]. The finding that HPVs 56
and 66 were significantly more prevalent in LG patients
across all three sites compared to HG patients is sup-
ported by a study that shows these two high-risk geno-
types to be found at > 10-fold higher prevalence in LSIL
lesions than in SCCs, suggesting that these are less likely
to persist or progress to malignancy [18].
It may be that this group of non-HIV+ women possess
inherent and, as yet undefined, specific inabilities to clear
HPV, which accounts for both the cervical dysplasia and
high rates of infection seen at all three sites. The presence
and expression of high-risk HPV at non-cervical sites is
likely to be insufficient for carcinogenesis on their own.
Indeed, a recent study has shown that in women from a
colposcopy cohort, only 8% of anal smears were positive
for high-risk HPV E6 and E7 mRNA, compared to 25% at
the cervix [19]. This suggests that there is a significant dif-
ference of expression, and hence activity of high-risk E6
and E7 at the anus, compared to the cervix. This may also
partially account for the fact that anal cancer rates are
much lower than those of the cervix. It has also been sug-
gested that co-factors, such as chronic oestrogen exposure
[20], can act to promote carcinogenesis in the cervix. The
presence of co-factors with weaker pro-oncogenic effects
at non-cervical mucosal sites may help explain the lower
frequencies of cancer observed in the anus and oro-
pharynx.
Conclusions
From this initial observational analysis, we show that
there is an extraordinarily high prevalence of HPV car-
riage at three different mucosal sites in HIV-negative
women attending a colposcopy clinic. Larger, case-con-
trolled studies, with negative controls focused particularly
on women with normal or negative smears, will be
required to establish more accurate prevalence data. The
hitherto undescribed and as yet, undefined specific
immune characteristics that have allowed persistence and
replication of HPV activity at the cervical site are also
likely to play a major role in the high prevalence of HPV
at the other mucosal sites. Therefore, these women may
represent a high-risk group for the development of non-
cervical HPV-related cancers. As the anal and oro-phar-
yngeal sites are not routinely monitored or treated for
dysplasia, this group of women may require surveillance
in the future.
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